Papers/PMID:41865069
Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.
Scientific reports2026The record
3 findings · 1 compound · 3 endpoints
What it reported
How to read these marksWhat moved
3 findings
atorvastatin — decreases C-reactive protein concentration
Evidence strength: moderate.Finding“CRP levels decreased significantly in both groups, though the magnitude of reduction was substantially greater in the atorvastatin group (p < 0.001), resulting in a highly significant between-group difference at 6 months (p < 0.001).”
Quoted verbatim from Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.. - Study
- RCT
- Dose
- 20 mg once daily
- Population
- Adults aged 18-75 with decompensated liver cirrhosis, atorvastatin 20 mg daily versus placebo for six months, both arms continuing standard-of-care therapies
Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.2026PMID:4186506910.1038/s41598-026-41326-4Permalink
atorvastatin — increases alanine aminotransferase
Evidence strength: moderate.Finding“Between-group comparisons after 6 months showed significantly higher ALT, AST, total bilirubin, and albumin levels in the atorvastatin group compared with placebo (all P < 0.001), whereas INR remained comparable between groups.”
Quoted verbatim from Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.. - Study
- RCT
- Dose
- 20 mg once daily
- Population
- Adults aged 18-75 with decompensated liver cirrhosis, atorvastatin 20 mg daily versus placebo for six months, both arms continuing standard-of-care therapies
Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.2026PMID:4186506910.1038/s41598-026-41326-4Permalink
atorvastatin — increases aspartate aminotransferase
Evidence strength: moderate.Finding“Between-group comparisons after 6 months showed significantly higher ALT, AST, total bilirubin, and albumin levels in the atorvastatin group compared with placebo (all P < 0.001), whereas INR remained comparable between groups.”
Quoted verbatim from Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.. - Study
- RCT
- Dose
- 20 mg once daily
- Population
- Adults aged 18-75 with decompensated liver cirrhosis, atorvastatin 20 mg daily versus placebo for six months, both arms continuing standard-of-care therapies
Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.2026PMID:4186506910.1038/s41598-026-41326-4Permalink